Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Oliver Jonas
- Study ID
- NCT06782399
- Phase
- EARLY_PHASE1
- Status
- Enrolling By Invitation
Conditions
- Squamous Cell Carcinoma
- Squamous Cell Carcinoma of the Skin
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Microdevice — COMBINATION_PRODUCTDevice: Microdevices The microdevice is an investigational miniaturized implantable nanodose drug delivery device. It was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. The microdevice releases nanodoses of several approved drugs into the tumor, and is then excised minimally invasively several days later. Other: Standard of care therapy Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
Study Details
This research study is studying the effect of different drugs as possible treatments for squamous cell carcinoma (SCC).
Key Dates
- Start date
- Oct 1, 2025
- Status verified
- May 2026
- Primary completion
- Jul 31, 2028
- Completion
- Jul 31, 2028
Study Design
- Enrollment
- 25 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Local treatment cohortLocal Treatment Cohort (5 participants) may recruit participants who plan to receive local surgical intervention (Mohs surgery or local excision) alone or in combination with further surgical treatment, radiation, or systemic therapy.
- Experimental: Systemic treatment cohortSystemic Treatment Cohort (20 patients) will not enroll until initial cohort has been completed (MD have been implanted, retrieved, and processed for immunohistochemical analysis). Microdevice protocol will be optimized given results derived from the local treatment cohort. Will include participants who plan to receive systemic therapy in the absence of additional local therapy (surgery or radiation). If patients receive systemic therapy, and there is clinical cutaneous residual disease after 12 weeks of systemic therapy, an additional 1 to 4 MDs will be implanted into residual cutaneous disease at this time.
Primary Outcome Measure
Feasibility of analysis [ Time Frame: through study completion, an average of 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana Farber Cancer Insitute | Boston | Massachusetts | 02115 | - |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · ImmVira Pharma Co. Ltd · Gilbert, Arizona
- Toripalimab With Chemotherapy for Sinus CancerPHASE2 · Recruiting · Glenn J. Hanna · Boston, Massachusetts
- PDT For Induction Therapy For Head And Neck CancerPHASE2 · Not Yet Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignPHASE2 · Recruiting · Christopher Wilke · Pittsburgh, Pennsylvania